Close menu



  • Major milestone achieved with new state-of-the-art microbiome facility spanning over 17,200 sq ft, completed within the 12-month timeframe, further enhancing bioproduction capabilities and contributing to the ecosystem in France and Europe
  • MaaT Pharma is Skyepharma’s Skyehub Bioproduction® first resident company
  • The facility was designed with the intent to support MaaT Pharma’s clinical-and commercial-scale manufacturing of Microbiome Ecosystem Therapies



Read the press release



More information